This expanded access program is an open-label, single-arm design where consenting patients may participate up until APT-1011 is commercially available in the relevant regions or the protocol is terminated by the Sponsor.
Patients will receive a 120-day supply of APT-1011 and will attend scheduled clinic visits every 4 months. Telephone visits will be performed as needed. At each clinic visit (or additional telephone visit), adverse events (AEs) and concomitant medications will be collected. The Global EoE score will be collected at clinic visits.
Study Type
EXPANDED_ACCESS
APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Del Sol Research Management LLC
Tucson, Arizona, United States
Arkansas Gastroenterology
North Little Rock, Arkansas, United States
Ventura County Gastroenterology Medical Group Camarillo
Camarillo, California, United States
FOMAT Medical Research
Glendale, California, United States
United Medical Doctors
Murrieta, California, United States
Medical Associates Research Group
San Diego, California, United States
Peak Gastroenterology Associates
Colorado Springs, Colorado, United States
Western States Clinical Research Inc
Wheat Ridge, Colorado, United States
Nuvance Health Medical Practice Ct, Inc.
Danbury, Connecticut, United States
Medical Research Center of Connecticut
Hamden, Connecticut, United States
...and 25 more locations